General
Preferred name
AMUVATINIB
Synonyms
MP470 ()
HPK 56 ()
Amuvatinib hydrochloride ()
MP470 hydrochloride ()
HPK 56 hydrochloride ()
HPK56, HPK-56, MP-470, MP-470.HCl, Amuvatinib HCl ()
MP470 (MP-470) ()
Amuvatinib (MP-470) ()
HPK-56 ()
HPK56 ()
MP 470 ()
MP-470 ()
Amuvatinib(mp470) ()
Amuvatinib ()
MP470.HCL ()
MP-470.HCl ()
HPK56 HCL ()
MP-470 HCI ()
MP470 HCI ()
P&D ID
PD011043
CAS
850879-09-3
1055986-67-8
Tags
available
drug candidate
probe
natural product
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Probe info
Probe selectivity
family-selective
Probe type
calculated probe
P&D approved
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
8
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Amuvatinib is an orally bioavailable, multitargeted receptor tyrosine kinase inhibitor. Some bioactivity data may be associated with the hydrochloride salt (PubChem CID 67254077).
(GtoPdb)
DESCRIPTION
Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp;onent of double-stranded DNA repair in cancer cells.
(PKIDB)
DESCRIPTION
Amuvatinib, also known as MP-470, is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. MP470 inhibits activities of other receptor tyrosine kinases. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
1
Compound Sets
21
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
Enamine BioReference Compounds
Guide to Pharmacology
LINCS compound set
MedChem Express Bioactive Compound Library
Other bioactive compounds
PKIDB
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
447.14
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
6
Aromatic Ring Count
4
cLogP
3.3
TPSA
75.89
Fraction CSP3
0.26
Chiral centers
0.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
RTK signaling
Protein Tyrosine Kinase/RTK
Angiogenesis
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Cell Cycle/DNA Damage
Apoptosis
Target
PDGFR
c-Kit
c-Kit (D816H)
FLT3 (D835Y)
PDGFR?? (V561D)
c-Met/HGFR
FLT3
RAD51
RET
KIT, MET
RTK inhibitor
KIT
MET
PDGFRB
Apoptosis related,c-Kit,c-Met,c-RET,FLT3,PDGFR,RAD51
Targets
KIT,PDGFRA,FLT3
MOA
FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor
Therapeutic Class
Anticancer Agents
Source data